FDA proposes allowing N-acetyl-L-cysteine (NAC) in dietary supplements, following a safety review and proposed regulatory changes under the FD&C Act.
Written By: Aabha Dey, BPharm
Reviewed By: Pharmacally Editorial Team
The U.S. Food and Drug Administration (FDA) on November 16, 2026, proposed reversing the exclusion of N-acetyl-L-cysteine (NAC) from the definition of dietary supplements. If finalised, the rule would allow NAC-containing products to be marketed as dietary supplements, provided they comply with applicable requirements of the Federal Food, Drug, and Cosmetic Act (FD&C Act). The proposal follows a comprehensive safety review and aims to resolve longstanding regulatory uncertainty surrounding NAC-containing products in the United States.
Why Was NAC Excluded from Dietary Supplements?
NAC was excluded under Section 201(ff)(3)(B) of the FD&C Act because it was approved as a drug before evidence of its marketing as a food or dietary supplement. The FDA first approved NAC on September 14, 1963, under New Drug Application (NDA) 013601, marketed as Mucomyst (acetylcysteine). The agency has not identified evidence that NAC was marketed as a food or dietary supplement before this approval.
Although NAC was marketed in the United States in products labelled as dietary supplements by August/September 1991, this did not overcome the earlier drug approval. Its pre-1994 marketing history means NAC is not considered a new dietary ingredient, but it remained subject to the separate statutory exclusion.
Previous FDA Position and Enforcement Discretion
In March 2022, the FDA responded to two citizen petitions and maintained that NAC-containing products could not legally qualify as dietary supplements under the existing statutory framework.
In August 2022, however, the agency issued final guidance announcing temporary enforcement discretion for certain NAC-containing products labelled as dietary supplements. The policy applied to products that would otherwise comply with the FD&C Act if NAC were not excluded from the dietary supplement definition. This provided a temporary enforcement approach without changing NAC’s formal legal status.
The FDA now intends to continue this policy while the proposed rule undergoes review. If finalised, the agency intends to withdraw the August 2022 enforcement discretion guidance.
Safety Review Supports the Proposed Change
The FDA conducted a systematic review of published studies involving orally administered NAC to assess its safety in or as a dietary supplement. The review identified 41 high-confidence studies, covering doses of up to 9,000 mg daily and treatment durations of up to three years.
Most studies reported no adverse events or no statistically significant differences in adverse events between NAC-treated participants and comparison groups. One study identified a statistically significant increase in nausea. Other reported adverse events included gastrointestinal discomfort, vomiting and rash. Based on the overall evidence, the FDA concluded that the level of concern associated with NAC-related adverse events was minimal, supporting a reasonable expectation of safety for its use in or as a dietary supplement.
The agency also evaluated whether allowing NAC in dietary supplements could affect pharmaceutical drug development. Its review identified at least 19 approved Abbreviated New Drug Applications (ANDAs) for acetylcysteine and 832 clinical trials involving NAC as a drug. The FDA noted that pharmaceutical research and development had continued alongside the sale of NAC-containing products labelled as dietary supplements for more than 30 years. It therefore found no reason to believe that removing the exclusion would negatively affect current or future NAC drug development.
What Would the Proposed Rule Change?
The FDA proposes establishing a new regulation, 21 CFR §190.1, titled “Dietary Ingredients Not Excluded from the Dietary Supplement Definition.” NAC would become the first ingredient listed under this provision, with scope for additional ingredients to be included in the future.
The proposed regulation addresses two provisions of the FD&C Act:
- Section 201(ff)(3)(B): The FDA would establish that NAC is not excluded from the dietary supplement definition, allowing its use in or as a dietary supplement.
- Section 301(ll): The agency would also provide that adding NAC to a dietary supplement is not a prohibited act under this provision, which otherwise restricts adding certain approved drugs to food, including dietary supplements.
Together, these measures would establish a formal legal pathway for eligible NAC-containing products rather than relying on temporary enforcement discretion.
However, the proposed change would not constitute FDA approval of individual NAC-containing supplements for safety or effectiveness. Manufacturers would remain subject to applicable dietary supplement requirements, including current good manufacturing practices under 21 CFR Part 111 and provisions addressing adulteration and misbranding.
Public Comment Period and Regulatory Implications
The proposed rule is identified under Docket No. FDA-2025-N-2699 and is scheduled for publication in the Federal Register on November 17, 2026. The FDA will accept public comments for 60 days following publication before deciding whether to issue a final rule.
The agency has also proposed that any final regulation become effective immediately upon publication. This remains subject to the outcome of the rulemaking process.
The proposal represents a significant regulatory development for NAC-containing dietary supplements, moving the ingredient from a position of statutory exclusion and temporary enforcement discretion towards a formal regulatory pathway. However, NAC will become eligible for lawful marketing under this mechanism only if the FDA finalises the proposed rule. Applicable product quality, manufacturing and labelling requirements will continue to apply.
References
U.S. Food and Drug Administration. FDA Issues Proposed Rule on NAC Products as Dietary Supplements. November 16, 2026.
U.S. Food and Drug Administration. Rulemaking to Provide That N-acetyl-L-cysteine Is Not Excluded from the Dietary Supplement Definition. Proposed Rule. Docket No. FDA-2025-N-2699.
U.S. Food and Drug Administration. Policy Regarding N-acetyl-L-cysteine: Guidance for Industry. August 2022.
About the Writer
Aabha Dey (LinkedIn) is a Pharmacy Bachelor from Delhi Pharmaceutical Sciences and Research University (DIPSAR), New Delhi. She has a strong interest in pharmacology, clinical research and medical writing, with practical exposure through internships in hospital practice, scientific and journal writing, and medical coding.
Her academic interests include pharmacovigilance, drug development, regulatory affairs and evidence-based healthcare communication. She is particularly interested in scientific research and translating complex pharmaceutical and clinical information into clear, accurate and accessible content.
